Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Phase III Trial to Assess Response Adapted Therapy Using FDG-PET Imaging in Patients With Newly Diagnosed, Advanced Hodgkin Lymphoma
Brief Summary: RATIONALE: Imaging procedures, such as fludeoxyglucose F 18 (FDG)-PET/CT scan, done before, during, and after chemotherapy may help doctors assess a patient's response to treatment and help plan the best treatment. It is not yet known whether FDG-PET/CT imaging is effective in assessing response to chemotherapy in patients with newly diagnosed Hodgkin lymphoma.

PURPOSE: This randomized phase III trial is studying FDG-PET/CT imaging to see how well it works in assessing response to chemotherapy in patients with newly diagnosed stage II, stage III, or stage IV Hodgkin lymphoma.


Options:
A: Arm Label: Arm I; Type: ACTIVE_COMPARATOR; Interventions: Biological: bleomycin sulfate, Drug: dacarbazine, Drug: doxorubicin hydrochloride, Drug: vinblastine sulfate | Arm Label: Arm II; Type: ACTIVE_COMPARATOR; Interventions: Drug: dacarbazine, Drug: doxorubicin hydrochloride, Drug: vinblastine sulfate | Arm Label: BEACOPP-14 chemotherapy; Type: EXPERIMENTAL; Interventions: Biological: bleomycin sulfate, Biological: filgrastim, Biological: pegfilgrastim, Drug: cyclophosphamide, Drug: doxorubicin hydrochloride, Drug: etoposide, Drug: prednisolone, Drug: procarbazine hydrochloride, Drug: vincristine sulfate | Arm Label: BEACOPP-escalated chemotherapy; Type: EXPERIMENTAL; Interventions: Biological: bleomycin sulfate, Biological: filgrastim, Biological: pegfilgrastim, Drug: cyclophosphamide, Drug: doxorubicin hydrochloride, Drug: etoposide, Drug: prednisolone, Drug: procarbazine hydrochloride, Drug: vincristine sulfate | Intervention Type: BIOLOGICAL; Name: bleomycin sulfate; Assigned to Arm(s): Arm I, BEACOPP-14 chemotherapy, BEACOPP-escalated chemotherapy | Intervention Type: BIOLOGICAL; Name: filgrastim; Assigned to Arm(s): BEACOPP-14 chemotherapy, BEACOPP-escalated chemotherapy | Intervention Type: BIOLOGICAL; Name: pegfilgrastim; Assigned to Arm(s): BEACOPP-14 chemotherapy, BEACOPP-escalated chemotherapy | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): BEACOPP-14 chemotherapy, BEACOPP-escalated chemotherapy | Intervention Type: DRUG; Name: dacarbazine; Assigned to Arm(s): Arm I, Arm II | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): Arm I, Arm II, BEACOPP-14 chemotherapy, BEACOPP-escalated chemotherapy | Intervention Type: DRUG; Name: etoposide; Assigned to Arm(s): BEACOPP-14 chemotherapy, BEACOPP-escalated chemotherapy | Intervention Type: DRUG; Name: prednisolone; Assigned to Arm(s): BEACOPP-14 chemotherapy, BEACOPP-escalated chemotherapy | Intervention Type: DRUG; Name: procarbazine hydrochloride; Assigned to Arm(s): BEACOPP-14 chemotherapy, BEACOPP-escalated chemotherapy | Intervention Type: DRUG; Name: vinblastine sulfate; Assigned to Arm(s): Arm I, Arm II | Intervention Type: DRUG; Name: vincristine sulfate; Assigned to Arm(s): BEACOPP-14 chemotherapy, BEACOPP-escalated chemotherapy
B: Arm Label: Favorable - Standard - any PET outcome; Type: ACTIVE_COMPARATOR; Interventions: Drug: ABVD q4 weeks, Radiation: IN-RT 30 Gy (+ boost 6 Gy residual), Procedure: FDG-PET scan | Arm Label: Favorable - Experimental - PET negative; Type: EXPERIMENTAL; Interventions: Drug: ABVD q4 weeks, Procedure: FDG-PET scan | Arm Label: Favorable - Experimental - PET positive; Type: EXPERIMENTAL; Interventions: Drug: BEACOPP escalated q3 weeks, Radiation: IN-RT 30 Gy (+ boost 6 Gy residual), Procedure: FDG-PET scan | Arm Label: Unfavorable - Standard - Any PET outcome; Type: ACTIVE_COMPARATOR; Interventions: Drug: ABVD q4 weeks, Radiation: IN-RT 30 Gy (+ boost 6 Gy residual), Procedure: FDG-PET scan | Arm Label: Unfavorable - Experimental - PET negative; Type: EXPERIMENTAL; Interventions: Drug: ABVD q4 weeks, Procedure: FDG-PET scan | Arm Label: Unfavorable - Experimental - PET positive; Type: EXPERIMENTAL; Interventions: Drug: BEACOPP escalated q3 weeks, Radiation: IN-RT 30 Gy (+ boost 6 Gy residual), Procedure: FDG-PET scan | Intervention Type: DRUG; Name: ABVD q4 weeks; Assigned to Arm(s): Favorable - Experimental - PET negative, Favorable - Standard - any PET outcome, Unfavorable - Experimental - PET negative, Unfavorable - Standard - Any PET outcome | Intervention Type: DRUG; Name: BEACOPP escalated q3 weeks; Assigned to Arm(s): Favorable - Experimental - PET positive, Unfavorable - Experimental - PET positive | Intervention Type: RADIATION; Name: IN-RT 30 Gy (+ boost 6 Gy residual); Assigned to Arm(s): Favorable - Experimental - PET positive, Favorable - Standard - any PET outcome, Unfavorable - Experimental - PET positive, Unfavorable - Standard - Any PET outcome | Intervention Type: PROCEDURE; Name: FDG-PET scan; Assigned to Arm(s): Favorable - Experimental - PET negative, Favorable - Experimental - PET positive, Favorable - Standard - any PET outcome, Unfavorable - Experimental - PET negative, Unfavorable - Experimental - PET positive, Unfavorable - Standard - Any PET outcome
C: Arm Label: Group 1 (favorable prognosis); Type: EXPERIMENTAL; Interventions: Biological: bleomycin sulfate, Drug: ABVD regimen, Drug: carmustine, Drug: dacarbazine, Drug: doxorubicin hydrochloride, Drug: etoposide, Drug: methylprednisolone, Drug: vincristine sulfate, Drug: vindesine | Arm Label: Group 2 (intermediate prognosis); Type: EXPERIMENTAL; Interventions: Biological: bleomycin sulfate, Drug: ABVD regimen, Drug: carmustine, Drug: dacarbazine, Drug: doxorubicin hydrochloride, Drug: etoposide, Drug: methylprednisolone, Drug: vincristine sulfate, Drug: vindesine | Arm Label: Group 3 (poor prognosis); Type: EXPERIMENTAL; Interventions: Drug: carmustine, Drug: cisplatin, Drug: cytarabine, Drug: dexamethasone, Drug: doxorubicin hydrochloride, Drug: etoposide, Drug: gemcitabine hydrochloride, Drug: ifosfamide, Drug: melphalan, Drug: methylprednisolone, Drug: mitoguazone, Drug: vindesine, Drug: vinorelbine tartrate, Procedure: allogeneic hematopoietic stem cell transplantation, Procedure: autologous hematopoietic stem cell transplantation | Intervention Type: BIOLOGICAL; Name: bleomycin sulfate; Assigned to Arm(s): Group 1 (favorable prognosis), Group 2 (intermediate prognosis) | Intervention Type: DRUG; Name: ABVD regimen; Assigned to Arm(s): Group 1 (favorable prognosis), Group 2 (intermediate prognosis) | Intervention Type: DRUG; Name: carmustine; Assigned to Arm(s): Group 1 (favorable prognosis), Group 2 (intermediate prognosis), Group 3 (poor prognosis) | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): Group 3 (poor prognosis) | Intervention Type: DRUG; Name: cytarabine; Assigned to Arm(s): Group 3 (poor prognosis) | Intervention Type: DRUG; Name: dacarbazine; Assigned to Arm(s): Group 1 (favorable prognosis), Group 2 (intermediate prognosis) | Intervention Type: DRUG; Name: dexamethasone; Assigned to Arm(s): Group 3 (poor prognosis) | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): Group 1 (favorable prognosis), Group 2 (intermediate prognosis), Group 3 (poor prognosis) | Intervention Type: DRUG; Name: etoposide; Assigned to Arm(s): Group 1 (favorable prognosis), Group 2 (intermediate prognosis), Group 3 (poor prognosis) | Intervention Type: DRUG; Name: gemcitabine hydrochloride; Assigned to Arm(s): Group 3 (poor prognosis) | Intervention Type: DRUG; Name: ifosfamide; Assigned to Arm(s): Group 3 (poor prognosis) | Intervention Type: DRUG; Name: melphalan; Assigned to Arm(s): Group 3 (poor prognosis) | Intervention Type: DRUG; Name: methylprednisolone; Assigned to Arm(s): Group 1 (favorable prognosis), Group 2 (intermediate prognosis), Group 3 (poor prognosis) | Intervention Type: DRUG; Name: mitoguazone; Assigned to Arm(s): Group 3 (poor prognosis) | Intervention Type: DRUG; Name: vincristine sulfate; Assigned to Arm(s): Group 1 (favorable prognosis), Group 2 (intermediate prognosis) | Intervention Type: DRUG; Name: vindesine; Assigned to Arm(s): Group 1 (favorable prognosis), Group 2 (intermediate prognosis), Group 3 (poor prognosis) | Intervention Type: DRUG; Name: vinorelbine tartrate; Assigned to Arm(s): Group 3 (poor prognosis) | Intervention Type: PROCEDURE; Name: allogeneic hematopoietic stem cell transplantation; Assigned to Arm(s): Group 3 (poor prognosis) | Intervention Type: PROCEDURE; Name: autologous hematopoietic stem cell transplantation; Assigned to Arm(s): Group 3 (poor prognosis)
D: Arm Label: doxorubicin + vinblastine + gemcitabine; Type: EXPERIMENTAL; Interventions: Drug: doxorubicin hydrochloride, Drug: gemcitabine hydrochloride, Drug: vinblastine, Procedure: fludeoxyglucose F 18 positron-emission tomography (PET) scan, Procedure: CT scan | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): doxorubicin + vinblastine + gemcitabine | Intervention Type: DRUG; Name: gemcitabine hydrochloride; Assigned to Arm(s): doxorubicin + vinblastine + gemcitabine | Intervention Type: DRUG; Name: vinblastine; Assigned to Arm(s): doxorubicin + vinblastine + gemcitabine | Intervention Type: PROCEDURE; Name: fludeoxyglucose F 18 positron-emission tomography (PET) scan; Assigned to Arm(s): doxorubicin + vinblastine + gemcitabine | Intervention Type: PROCEDURE; Name: CT scan; Assigned to Arm(s): doxorubicin + vinblastine + gemcitabine

Answer: A